CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

The Lancet
Original article

[Articles] [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial

Phase 3PSMA-617
Related Companies

Read the original article

Published by The Lancet on August 6, 2026 10:30 PM

Read Original